[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rachel Miller\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100599870","pitch---impacting-hereditary-cancer-testing-100599870",false,"NCT07090109","PITCH - Impacting Hereditary Cancer Testing","Partnering to Impact Testing in the Commonwealth for Hereditary Cancers (PITCH)","Inclusion Criteria:\n\n* diagnosed with a cancer that can be associated with hereditary forms of cancer\n\nExclusion Criteria:\n\n* previously undergone multi-gene panel testing for hereditary cancers","FEMALE","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to assess patients' knowledge and attitudes about genetic testing before and after viewing an educational video. The main questions it aims to answer are:\n\n* Did the video change participants' knowledge and attitudes about genetic testing?\n* Did participants make an informed choice about pursuing genetic testing?\n\nParticipants will:\n\n* Complete a baseline survey\n* View educational video\n* Complete follow-up survey",[26,27,28],"Ovarian Cancer","Genetic Testing","Genetic Counseling","NOT_YET_RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":20},"2026-08",{"date":37,"type":20},"2027-07",{"name":39,"class":40},"Rachel Miller","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100292646","phase-2-evaluating-genomic-testing-in-human-cancer--outcomes-of-targeted-therapies-100292646","NCT03089554","Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies","Integration of Precision Medicine Into Cancer Therapeutics, Part 2: A Therapeutic Phase 2 Sub-study Evaluating Genomic Testing in Human Cancer and Outcomes of Targeted Therapies Recommended by an Institutional Multidisciplinary Molecular Tumor Board in Patients With Poor Prognosis Cancer","Inclusion Criteria:\n\n* Patients with clinically suspected or histologically confirmed solid or hematological malignancy who have undergone or will undergo genetic testing of their tumor\n* Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.\n* Patients must have either measurable or non-measurable disease.\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group performance status ≤3.\n* Patients with brain metastasis must have had treatment of their brain metastasis completed at least 1 day prior to enrollment and be on stable dose of steroids or off steroids at the time of enrollment.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with targeted therapy, in the opinion of the treating physician.\n* Pregnant women are excluded from this study.\n* HIV positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible.","ALL",{"count":51,"type":20},93,[53],"PHASE2","This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).",[56],"Cancer","RECRUITING","2026-05-21",{"date":60,"type":33},"2026-05-27",{"date":62,"type":33},"2017-04-11",{"date":64,"type":20},"2027-04",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100568122","mcc-24-gyn-11-comparison-of-nodal-sampling-in-endometrial-cancer-100568122","NCT06677112","MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer","Randomized Phase 3 Study of SELECTIVE SURGICAL STAGING Versus REFLEX Lymphadenectomy in Non-mappers Undergoing Sentinel Lymph Node Sampling for the Treatment of Endometrial Cancer","Inclusion Criteria:\n\n* Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy\n* Histologically or cytologically confirmed carcinoma of the endometrium confined to the uterine corpus\n* No clinical evidence of extra-uterine disease on pre-operative evaluation. Preoperative evaluation to rule-out extra-uterine disease may include a CT scan, MRI or ultrasound. Note: preoperative imaging is not mandatory for study enrollment.\n* Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.\n\nNeoadjuvant chemotherapy for this endometrial cancer is not allowed.\n\n* Life expectancy (estimated survival) of at least 6 months.\n* AST(SGOT)\u002FALT(SGPT) \\\u003C 3.0X upper limit of normal\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* GOG Performance Status greater than 2 (Appendix II)\n* Uterine sarcoma\n* Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam\n* Previous vaginal, pelvic or abdominal irradiation\n* Chemotherapy or immunotherapy directed at the present disease\n* Previous pelvic lymphadenectomy or retroperitoneal surgery\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen should be excluded\n* Known allergy to iodine or indocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition\n* Patients with uncontrolled intercurrent illness\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant or lactating women. Women of child-bearing potential will be excluded if they have a positive serum\u002Furine pregnancy test",{"count":74,"type":20},625,[23],"This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. This study will gather information to help determine the best way to evaluate lymph nodes during surgery for endometrial cancer.",[78],"Endometrial Cancer",[80,81],"selective surgical staging","lymphadenectomy","2025-11-11",{"date":84,"type":33},"2025-11-13",{"date":86,"type":33},"2025-03-17",{"date":88,"type":20},"2030-01",{"name":39,"class":40},""]